Status:
ACTIVE_NOT_RECRUITING
Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib
Lead Sponsor:
South Valley University
Conditions:
Alopecia Areata
Eligibility:
All Genders
12-60 years
Phase:
PHASE1
Brief Summary
Assess serum and tissue retinol binding protein 4 in patients with severe alopecia areata in correlation with healthy individuals . Estimate genetic profile of retinol binding protein4 in severe alop...
Detailed Description
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle .It is a multifactorial disease in which environmental, neuro-endocri...
Eligibility Criteria
Inclusion
- Patients at least 12 years old not more than 60 with severe alopecia areata, multiple or /with not responding to usual treatment
Exclusion
- Patients with scarring alopecia.
- Patients less than 12 years old or more than 60.
- Patients with active inflammatory disease or immuncompromised.
- Patients with infection or malignancy .
- Patients with antiepileptic drugs or psychotics .
- Pregnancy and lactation .
- Patients with abnormal lipid profile.
- Patients with bleeding or thrombotic tendency.
- Patients taking other JAK inhibitors or cyclosporine or immunosuppressive drugs.
- Patients with active herpes zoster or have tendency for recurrence.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06545110
Start Date
September 1 2023
End Date
October 30 2024
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
South Valley University
Qina, الكيلو 6 Qena - Safaga Rd, Qena, Qena Governorate, Egypt, +20963211279